



Legislation Details (With Text)

File #: 21-0737 **Version:** 2 **Name:** 4/19/21 Resolution Declaring September 2021 Entheogenic Plant and Fungi Awareness Month

Type: Resolution **Status:** Lay on Table

File created: 4/19/2021 **In control:** City Council

On agenda: 4/19/2021 **Final action:** 4/19/2021

Enactment date: **Enactment #:**

Title: Resolution Declaring September Entheogenic Plant and Fungi Awareness Month in Ann Arbor, Michigan

Sponsors: Jeff Hayner, Kathy Griswold

Indexes:

Code sections:

Attachments:

Date	Ver.	Action By	Action	Result
4/19/2021	2	City Council		
4/19/2021	2	City Council	Lay on the table	Pass

Resolution Declaring September Entheogenic Plant and Fungi Awareness Month in Ann Arbor, Michigan

Whereas, Substance abuse, addiction, recidivism, trauma, post-traumatic stress symptoms, chronic depression, severe anxiety, end of life anxiety, grief, cluster headaches, and other debilitating conditions are present in our community;

Whereas, The use of entheogenic plants/fungi has been shown by scientific and clinical studies and traditional practices to be beneficial to the health and well-being of individuals and communities in addressing these conditions, as well as personal spiritual growth;

Whereas, practices with entheogenic plants/fungi have been considered sacred to human cultures and human relationships with nature for thousands of years;

Whereas, Clinical studies and research in the U.S., Canada and Europe have shown the safety and efficacy of entheogenic plants/fungi for treating a variety of mental health illnesses going back to the 1960s;

Whereas, The City of Ann Arbor on September 21, 2020 made entheogenic plants the lowest law enforcement priority and on January 12, 2021 Washtenaw County released a similar entheogenic plant policy, and a sacred plant and mushroom festival (Entheo Fest) will become an annual in event in September of every year in Ann Arbor starting on September 19, 2021.

Whereas, The FDA has granted Breakthrough Therapy Designation to Psilocybin for use in major depressive disorders; Psilocybin has been shown to ease treatment resistant depression, end-of-life anxiety, and cluster headaches, Ibogaine has been shown to be an effective treatment for opiate

addiction, and Ayahuasca studies are currently underway to better understand its ability to address depression, and substance dependence; and

RESOLVED, The Ann Arbor City Council hereby proclaim September, to be Entheogenic Plant and Fungi Awareness Month in Ann Arbor, Michigan; and

RESOLVED, The Ann Arbor City council calls upon our citizens, government agencies, public and private institutions, and businesses, to commit to increasing the awareness and understanding of the potential benefits of entheogens for mental health, personal and spiritual growth, as well as honoring the long standing ancestral practices and relationships with entheogens.

References:

Entheogens for Personal and Spiritual Growth

Frecska, E., et al. (2012). Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies. Journal of Psychoactive Drugs 44(3), pp. 191-199.

Hartogsohn, I. (2018). The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity. Frontiers in Neuroscience, 12 (129). doi:10.3389/fnins.2018.00129

MacLean, K., et al. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11)1453-1461.

Moro, L., et al. (2011) Voice of the Psychonauts: Coping, Life Purpose, and Spirituality in Psychedelic Drug Users. Journal of Psychoactive Drugs, 43 (3), pp.188-198. DOI: 10.1080/02791072.2011.605661

Nour, M., et al. (2017): Psychedelics, Personality and Political Perspectives. Journal of Psychoactive Drugs. DOI:10.1080/02791072.2017.1312643

Sweat, N., et al. (2016). The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. Journal of Psychoactive Drugs, 48(5), pp. 344-350, DOI: 10.1080/02791072.2016.1234090

Historical Use of Entheogens

*El-Seedi, H., et al. (2005). Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of *Lophophora* from Texas. Journal of Ethnopharmacology 107(1), pp. 238-242.*

Guzman, G. (2008). Hallucinogenic Mushrooms in Mexico: An Overview. Economic Botany, 62(3), pp. 404-412.

Miller, L. et al., (2019). Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-

old ritual bundle from South America. Proceedings of the National Academy of Sciences. DOI :10.1073/pnas. 190217411

Samorini, G. (1992). The Oldest Representations Of Hallucinogenic Mushrooms In The World (Sahara Desert, 9000 - 7000 B.P.). Integration, Journal of Mind-Moving Plants and Culture 2/3.

Psilocybin for End-of-Life Anxiety

Blinderman, C. (2016). Psycho-existential distress in cancer patients: A return to entheogens. Journal of Psychopharmacology 30 (12), pp. 1205-1206.

Kelmendi, B., et al. (2016). The role of psychedelics in palliative care reconsidered: A Case for psilocybin. Journal of Psychopharmacology 30(12), pp. 1212-1214.

Ross, S., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), pp. 1165-1180.

Psilocybin and Treatment-Resistant Depression

Hendricks, P., et al. (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 29(9), pp. 1041-1043.

Lyons, T. and Carhart-Harris, R. (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 32 (7), pp. 811-819.

Entheogens and Reduced Recidivism

Hendricks, P., et al. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal Of Psychopharmacology 28(1), pp. 62-66.

Walsh, Z. , et al. (2016). Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology, pp. 1-7. DOI: 10.1177/0269881116642538.

Psilocybin and Cluster Headaches

Schindler, E. et al., (2015) Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey, Journal of Psychoactive Drugs, 47(5),pp. 372-381. DOI: 10.1080/02791072.2015.1107664

Iboga/Ibogaine for Addiction Therapy

Alper, K., et al. (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal of

Addictions, 8(3), 234-242. doi:10.1080/105504999305848

Brown, T. K. (2013). *Ibogaine in the treatment of substance dependence*. *Current Drug Abuse Reviews*, 6(1), 3-16. doi: 10.2174/15672050113109990001

Brown, T. and Alper, K. (2017): *Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes*. *The American Journal of Drug and Alcohol Abuse*. DOI: 10.1080/00952990.2017.1320802

Luciano, D. (1998). *Observations on treatment with ibogaine*. *American Journal of Addictions*, 7(1), pp. 89-89. doi:10.1111/j.1521-0391.1998.tb00472.x

Mash, D., et al. (2001). *Ibogaine in the treatment of heroin withdrawal*. In K. Alper, & G.A. Cordell (Eds.), *The alkaloids: Chemistry and biology* (1st ed., Vol. 56, pp. 155-171). London: Academic Press/Elsevier.

Mash, D., et al., (2018) *Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes*. *Frontiers in Pharmacology*. 9:529. doi:10.3389/fphar.2018.00529

Sheppard, S. G. (1994). *A preliminary investigation of ibogaine: Case reports and recommendations for further study*. *Journal of Substance Abuse Treatment*, 77(4), 379-385. doi: 10.1016/0740-5472(94)90049-3

Ayahuasca for Addiction Therapy

Barbosa, P. et al. (2018) *Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca*. *Frontiers in Psychiatry*, 9 (136).doi:10.3389/fpsy.2018.00136

Brierley, D., and Davidson, C. (2012). *Developments in harmine pharmacology -Implications for ayahuasca use and drug-dependence treatment*. *Progress in Neuropsychopharmacology & Biology* 39(2), pp. 263-272.

Liester, M. and Prickett, J. (2012) *Hypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions*. *Journal of Psychoactive Drugs*, 44 (3),pp. 200-208. DOI: 10.1080/02791072.2012.704590

Loizaga-Velder, A., and Verres R. (2014). *Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence-qualitative results*. *Journal of Psychoactive Drugs* 46(1), pp. 63-72.

Mabit, J., et al. (1996). *Takiwasi: The Use of Amazonian Shamanism to Rehabilitate Drug Addicts*. *Yearbook of Cross-Cultural Medicine and Psychotherapy*. W. Andritzky. Berlin, International Institute of Cross-Cultural Therapy Research.

Talina, P., and Sanabriab, E. (2017). *Ayahuasca's entwined efficacy: An Ethnographic study of ritual*

healing from addiction. *International Journal of Drug Policy* 44, pp. 23-30.

Thomas, G., et al. (2013). *Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Current Drug Abuse Review* 6(1), pp. 30-42.

Ayahuasca and Depression

Anderson, B. (2012). *Ayahuasca as Antidepressant? Psychedelics and Styles of Reasoning in Psychiatry. Anthropology of Consciousness*, 23(1), pp. 44-59.

de L. Osorio, F., et al. (2015). *Antidepressant effects of a single dose of ayahuasca inpatients with recurrent depression: a preliminary report. Revista Brasileira de Psiquiatria* 37(1), pp. 13-20.

Palhano-Fontes, F., et al. (2014). *The Therapeutic Potentials of Ayahuasca in the Treatment of Depression. The Therapeutic Use of Ayahuasca. B. C. Labate and C. Cavnar, Springer: Berlin, Heidelberg*, pp. 23-39.

dos Santos, R., et al. (2016). *Anti-depressive, anxiolytic, and anti-addictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology*, 6(3), pp. 193-213.

doi:10.1177/2045125316638008